Cervical Biopsy in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS (INDICATIONS):

• Women with an abnormal cervical cytology result: ASC-US (atypical squamous cells of undetermined significance) with a positive hrHPV reflex test, LSIL, HSIL, ASC-H, AGC, or any squamous cell carcinoma/adenocarcinoma cytological finding

• Positive primary hrHPV screening (genotypes 16/18 or other high-risk types on cobas, Aptima, or equivalent validated assay)

• Colposcopically detected acetowhite lesions, punctation, mosaic vascular patterns, or atypical vessels in the transformation zone (TZ types 1, 2, or 3 per IFCPC 2011 nomenclature)

• Visible or palpable cervical lesions on examination regardless of cytology result

• Post-treatment surveillance following prior LEEP, cone biopsy, or ablative therapy for CIN

• Unexplained intermenstrual, post-coital, or post-menopausal bleeding with cervical abnormality on examination

• Abnormal VIA/VILI finding in resource-adapted screening programmes

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• Current cervical cytology and hrHPV genotyping report (LBC preferred)

• Full blood count (FBC) and coagulation profile (PT/INR, aPTT) — mandatory to exclude bleeding diathesis

• Blood group and type

• High-vaginal swab (HVS) culture to rule out active cervicitis or Trichomonas/bacterial vaginosis, which must be treated prior to biopsy

• Pregnancy test (urine or serum β-hCG) — biopsy in pregnancy requires specialist counselling and modified technique

• Pelvic ultrasound if endometrial or adnexal pathology is clinically suspected

• MRI pelvis (3T) if frank invasive carcinoma is suspected clinically, to assess parametrial involvement and guide staging

• Cystoscopy/proctoscopy and PET-CT or CT thorax-abdomen-pelvis reserved for confirmed invasive carcinoma at staging workup

• CONTRAINDICATIONS & SPECIAL CONSIDERATIONS:

• Active menstruation (biopsy deferred to follicular phase where possible to minimise bleeding and improve colposcopic visualisation)

• Active lower genital tract infection — treat first, then biopsy

• Confirmed intrauterine pregnancy beyond the first trimester (relative contraindication; biopsy of CIN 2+ may be deferred to postpartum period after careful MDT review)

• Severe coagulopathy or anticoagulation therapy (warfarin, DOACs) not bridged appropriately — haematology input required

• Known allergy to local anaesthetic agents (lignocaine/lidocaine) — anaesthesia team review required

• Patient inability to tolerate lithotomy position (modified positioning or general anaesthesia under consideration)

BIOPSY TECHNIQUES — STANDARD APPROACHES:

1. COLPOSCOPY-DIRECTED PUNCH BIOPSY (Most Common)

Performed under direct colposcopic visualisation after application of 3–5% acetic acid (revealing acetowhite epithelium) and Lugol's iodine (identifying iodine-non-staining areas — VILI positive). A Tischler, Baby Tischler, or Eppendorfer forceps is used to excise 3–5 mm tissue cylinders from the most abnormal-appearing areas of the TZ. Two to four targeted biopsies are taken from discrete lesion quadrants to maximise diagnostic yield. Local anaesthetic (1–2 mL of 1% lignocaine with 1:100,000 adrenaline) is applied to the biopsy site via a 25-gauge needle to minimise discomfort. Haemostasis is achieved with ferric subsulfate (Monsel's solution) or silver nitrate; no suturing is required.

2. ENDOCERVICAL CURETTAGE (ECC)

Performed with a Kevorkian or Randall curette to sample the endocervical canal when the squamocolumnar junction (SCJ) is not fully visualised (TZ type 3), when cytology suggests glandular abnormality (AGC/AIS), or in post-menopausal women. ECC is contraindicated in pregnancy. The specimen is submitted separately from ectocervical biopsies to precisely localise disease extent.

3. LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE (LLETZ) / LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP)

A 'see-and-treat' therapeutic-diagnostic approach increasingly employed in a single colposcopy visit when cytology and colposcopy are both high-grade (HSIL on cytology + Grade 2 colposcopy). A tungsten wire loop (typically 20×10 mm or 25×10 mm) carries a blended electrosurgical current (cut: 35–55 W; coagulation: 40–60 W) that excises the entire TZ en bloc as a single specimen, preserving histological architecture for precise margin assessment. The depth of excision (typically 7–10 mm for ectocervical CIN; 15–25 mm for endocervical extension) is guided by colposcopic findings. LLETZ produces a definitive histological specimen superior to punch biopsy for excluding microinvasive carcinoma (FIGO stage IA1). Thermal artefact at margins is minimised by experienced operators using appropriate loop sizing and single-pass technique.

4. COLD-KNIFE CONE BIOPSY (CKC)

Performed under general or spinal anaesthesia in an operating theatre. A scalpel excises a cone-shaped specimen extending from the ectocervix into the endocervical canal (depth 15–25 mm; cone angle adapted to colposcopic lesion extent). CKC is preferred over LLETZ when: (a) microinvasive carcinoma (FIGO IA1/IA2) needs margin assessment free of thermal artefact; (b) AIS is confirmed on punch biopsy (to assess glandular margin status); (c) a previous LLETZ had involved margins; or (d) the lesion extends into the endocervical canal beyond the reach of a standard LEEP loop. Haemostasis is achieved with interrupted Vicryl 0 sutures and electrocautery.

5. LASER CONISATION

CO₂ laser at 20–30 W delivers a high-precision excision with a very narrow zone of thermal damage (< 1 mm), producing superior-quality histological margins compared to LLETZ. It is particularly advantageous in women with prior cervical surgery where preservation of cervical stroma is paramount (fertility-sparing considerations). Available in select tertiary centres in Mumbai, Delhi, and Dubai affiliated with GAF Healthcare.

6. ADVANCED DIAGNOSTIC ADJUNCTS:

• p16/Ki-67 dual immunostaining (CINtec PLUS): Applied to LBC slides or biopsy sections to objectively distinguish productive HPV infection (CIN 1) from transforming HPV infection (CIN 2/3), reducing unnecessary treatment referrals by 30–40%.

• HPV Genotyping with Extended Typing (28-type panels): Identifies concurrent high-risk genotypes beyond 16/18, informing risk-stratified surveillance intervals.

• Next-Generation Sequencing (NGS) of FFPE biopsy tissue: Used in specialised oncology centres when invasive carcinoma is confirmed, to assess PIK3CA, KRAS, and PD-L1 status relevant to systemic treatment planning.

• Digital Colposcopy with AI-Assisted Image Analysis: Several GAF partner hospitals in Bangalore, Chennai, and Dubai employ validated AI colposcopy platforms (e.g., EVA colposcope) that provide real-time grading assistance, improving detection of CIN 2+ by 15–20% over unaided colposcopy in controlled studies.

PRE-PROCEDURE PHASE (Days –14 to –1):

Step 1 — GAF Healthcare Intake & Medical File Review (Day –14 to –10) The patient uploads all existing cytology reports, HPV test results, prior colposcopy images, imaging, and blood results to the secure GAF patient portal. A GAF-affiliated gynaecological oncologist reviews the file within 24–48 hours and provides a written pre-assessment confirming indication, preferred biopsy technique, and any additional investigations needed on arrival.

Step 2 — Pre-Travel Investigations (Day –10 to –3) If not already available, the patient completes FBC, coagulation profile, HVS culture, β-hCG, and cervical cytology/HPV co-test at a local laboratory. Results are uploaded to the portal. Active cervicitis is treated with appropriate antibiotics (e.g., metronidazole 400 mg twice daily for 7 days for BV) before travel.

Step 3 — Arrival & Logistics (Day –1) GAF Healthcare arranges airport pickup, hotel or serviced apartment accommodation within 10–20 minutes of the partner hospital, and a dedicated patient liaison officer (PLO) who speaks the patient's language. The PLO accompanies the patient to all appointments and handles all administrative and translation needs.

Step 4 — Hospital Pre-Admission Assessment (Day 0, Morning) The patient attends the hospital for vital signs, weight, blood pressure, and a brief gynaecological history update. Consent is obtained in the patient's language with interpreter support. NPO (nil-by-mouth) instructions apply only if general/spinal anaesthesia is planned for CKC or laser conisation (4–6 hours fasting for solids; 2 hours for clear fluids per ASA fasting guidelines).

PROCEDURE PHASE (Day 0):

Step 5 — Anaesthesia & Positioning For punch biopsy and LEEP: the patient is placed in the dorsal lithotomy position. Local anaesthetic (1% lignocaine with adrenaline) is injected paracervically or directly into biopsy sites. Oral anxiolytic (e.g., lorazepam 1 mg) may be offered. Total procedural time: 15–30 minutes. For CKC or laser conisation: spinal or general anaesthesia is administered in the operating theatre; procedural time: 30–60 minutes.

Step 6 — Colposcopy, Tissue Excision & Haemostasis The gynaecologist performs digital HD colposcopy, applies acetic acid and Lugol's iodine, identifies and photographs the target lesion, then proceeds with the planned biopsy technique (punch/ECC/LEEP/CKC/laser as determined pre-operatively). Biopsy specimens are placed immediately in labelled formalin containers. Haemostasis is confirmed before instrument removal. For LEEP/CKC, a vaginal pack may be placed for 4–6 hours.

Step 7 — Recovery & Discharge Punch biopsy / LEEP: Patient rests in the recovery area for 1–2 hours, observed for active vaginal bleeding. Discharge on the same day with written aftercare instructions, a supply of ibuprofen 400 mg (analgesic) or paracetamol 1 g (for patients contraindicated to NSAIDs), and an antiseptic vaginal pessary if prescribed. CKC / Laser conisation: Overnight hospital admission for haemostasis monitoring; discharge the following morning.

POST-PROCEDURE RECOVERY PHASE (Days 1–14):

Step 8 — Immediate Post-Procedure Expectations (Days 1–5) Mild-to-moderate lower abdominal cramping is expected for 24–48 hours (managed with oral analgesics). A dark-brown, Monsel's solution-related vaginal discharge or light spotting is normal for 5–10 days. The patient is advised to: avoid tampon use, sexual intercourse, swimming, and heavy lifting for a minimum of 4 weeks (especially post-LEEP/CKC). Shower bathing is permitted from Day 1.

Step 9 — Histopathology Result (Days 2–5 post-biopsy) FFPE processing and H&E reporting with p16/Ki-67 dual-stain are completed within 48–72 hours at accredited partner hospitals. The GAF PLO notifies the patient when results are ready and facilitates a teleconsultation or in-person meeting with the gynaecological oncologist, who explains findings and provides a written management plan (active surveillance, excision, or oncology referral).

Step 10 — Fit-to-Fly Assessment & Departure (Days 7–14) For punch biopsy alone: fit to fly within 5–7 days provided there is no active bleeding. For LEEP: fit to fly at 7–10 days. For CKC or laser conisation: fit to fly at 10–14 days. GAF Healthcare provides a formal Fit-to-Fly medical clearance letter for the patient's airline and travel insurer.

Step 11 — Home-Country Follow-Up Coordination (Weeks 2–12) GAF Healthcare shares a structured follow-up protocol with the patient's home gynaecologist: repeat LBC and hrHPV co-test at 6 months (post-LEEP/CKC) or per the management plan for CIN 1 (12-month cytology/HPV surveillance). Virtual follow-up consultations with the treating GAF-partner gynaecologist are available at 4 weeks and 3 months post-procedure.